Abstract: An analog-digital converter includes a count code generator to receive a code generation clock signal from a clock signal generator and to output a count code according to the code generation clock signal, a latch to latch the count code, an operating circuit to generate a count value of the count code and to output a digital signal based on the count value, and a transfer controller to transfer the count code from the latch to the operating circuit. The transfer controller determines whether to transfer the count code according to a logic level of a count enable clock signal generated from the clock signal generator.

Abstract: The present disclosure is generally directed to antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g. a mammalian MerTK or human MerTK, and use of such compositions in preventing, reducing risk, or treating a disease or disorder an individual in need thereof.

Abstract: An embodiment mounting and demounting device for a wireless electronic device includes a pair of holder wings arranged symmetrically to each other and configured to press both sides of the wireless electronic device, a holder wing adjusting device configured to apply a force to adjust a gap between the holder wings using a driving force of a drive motor, a lifting implementing device configured to interlock with the holder wing adjusting device to lift the wireless electronic device upward in a case in which the holder wings are spread apart by a predetermined reference gap or more, a lower housing wrapped around a lower side of the holder wings, the holder wing adjusting device, and the lifting implementing device, and an upper housing coupled to an upper side of the lower housing and configured to allow the wireless electronic device to pass through in an up and down direction.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.

Abstract: When a towing vehicle is driven while towing a towed vehicle having driving force, a controller of the towed vehicle determines wheel slip of the towing vehicle based on driving information of the towing vehicle and determines wheel slip of the towed vehicle based on driving information of the towed vehicle, and upon determining that wheel slip of the towing vehicle or the towed vehicle has occurred or upon determining that wheel slip of each of the towing vehicle and the towed vehicle has occurred, control to increase or decrease driving force of the towed vehicle or control to change the driving force distribution ratio between left and right wheels of the towed vehicle is performed, whereby it is possible to improve driving stability and rough road escape performance of the towing vehicle and the towed vehicle.

Abstract: The present disclosure is generally directed to compositions that include bispecific antibodies, e.g., monoclonal antibodies, that specifically bind a MerTK polypeptide (e.g., a mammalian MerTK or human MerTK) and a PDL1 polypeptide (e.g. a mammalian PDL1 polypeptide or human PDL1 polypeptide), and use of such compositions in treating an individual in need thereof.

Abstract: The present disclosure is generally directed to compositions that include monovalent antibodies, e.g., monoclonal monovalent antibodies that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK polypeptide or human MerTK polypeptide, and use of such compositions in treating an individual in need thereof.

Abstract: A display device includes a display panel including a display area in which pixels are placed to display an image, and a non-display area located around the display area; and a cover window including a light blocking area overlapping the non-display area of the display panel in a thickness direction of the display panel, and a through hole penetrating through the light blocking area, wherein the display panel further includes a first power supply line located in the non-display area to apply a first power supply voltage, and wherein the first power supply line does not overlap the through hole in the thickness direction of the display panel.

Abstract: In one example, a semiconductor device can comprise a substrate, a device stack, first and second internal interconnects, and an encapsulant. The substrate can comprise a first and second substrate sides opposite each other, a substrate outer sidewall between the first substrate side and the second substrate side, and a substrate inner sidewall defining a cavity between the first substrate side and the second substrate side. The device stack can be in the cavity and can comprise a first electronic device, and a second electronic device stacked on the first electronic device. The first internal interconnect can be coupled to the substrate and the device stack. The encapsulant can cover the substrate inner sidewall and the device stack and can fill the cavity. Other examples and related methods are disclosed herein.

Abstract: An infrared adaptive transparent camouflage film includes a substrate, a graphene layer, an electrode layer and an ion gel layer. The substrate has dielectric. The graphene layer is disposed on the substrate and stacked in multiple layer. The electrode layer is disposed over the substrate and is spaced apart from the graphene layer. The ion gel layer is disposed over the graphene layer and the electrode layer, or disposed between the graphene layer and the electrode layer, to dope the graphene layer electrically.

Abstract: A forced airflow drying apparatus includes a body including a pair of air inlets to receive inlet air which is channeled to an upstream side of a filter unit, a pair of body airflow generators to generate a first forced airflow, each body airflow generator having a first end and a second end, where the first end of each body airflow generator is opened to a downstream side of the filter unit, a pair of thermoelectric devices configured to control a temperature of the first forced airflow, and a first air outlet, in communication with the second end of each body airflow generator, to receive the forced airflow from the body airflow generators and to expel the forced airflow out of the body.

Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.

Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.

Abstract: The invention provides adenosine deaminase variants that are capable of deaminating adenine and/or cytosine in a target polynucleotide (e.g., DNA). The disclosure also provides multi-molecular complexes, fusion proteins, base editors, and base editor systems comprising the adenosine deaminase variants with adenine and cytosine deaminase activity and/or cytosine deaminase specificity, and methods of use thereof.

Abstract: The disclosure provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using these adenosine deaminase variants for editing a target sequence.

Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.

Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.